Revenue Update on Idera Pharmaceuticals Inc(NASDAQ:IDRA)

Idera Pharmaceuticals Inc(NASDAQ:IDRA) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 15, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $15.281M. Analysts estimated a revenue of $150.000K. The revenues were 10,087.33% below the estimates. Earnings per share were $0.01. The reported EPS was above estimates by 109.09%. Analysts had estimated an EPS of $-0.11.

Idera Pharmaceuticals Inc (IDRA) made into the market gainers list on Fridays trading session with the shares advancing 3.52% or 0.07 points. Due to strong positive momentum, the stock ended at $2.06, which is also near the day’s high of $2.07. The stock began the session at $1.93 and the volume stood at 23,74,277 shares. The 52-week high of the shares is $3.33 and the 52 week low is $1.19. The company has a current market capitalization of $307 M and it has 14,90,93,720 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Oct 5, 2016, Youssef El Zein (director 10% owner) purchased 4,228 shares at $2.56 per share price.Also, On Oct 5, 2016, Maxine Gowen (director) purchased 4,102 shares at $2.56 per share price.On May 13, 2016, Mark J Casey (Senior VP & General Counsel) purchased 34,450 shares at $1.44 per share price, according to the Form-4 filing with the securities and exchange commission.

Idera Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery development and commercialization of therapeutics for oncology and rare diseases. The Company uses two drug discovery technology platforms to design and develop drug candidates. Using its Toll-like receptor (TLR) targeting technology the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its gene silencing oligonucleotide (GSO) technology the Company is developing GSOs to turn off the messenger RNA (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400 for Waldenstrom’s macroglobulinemia and diffuse large B-Cell lymphoma; IMO-2055/IMO-2125 for immune-oncology; IMO-8400 for dermatomyositis and Duchenne Muscular Dystrophy (DMD) and IMO-9200 for selected autoimmune disease.

Add Comment